| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 469 | 2019 |
| Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers H Vasen, I Ibrahim, CG Ponce, EP Slater, E Matthäi, A Carrato, J Earl, ... Journal of Clinical Oncology 34 (17), 2010-2019, 2016 | 349 | 2016 |
| Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design G Castano-Vinyals, N Aragonés, B Pérez-Gómez, V Martín, J Llorca, ... Gaceta sanitaria 29, 308-315, 2015 | 211 | 2015 |
| Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer J Earl, S Garcia-Nieto, JC Martinez-Avila, J Montans, A Sanjuanbenito, ... BMC cancer 15, 1-10, 2015 | 190 | 2015 |
| Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib AC Mena, EG Pulido, C Guillen-Ponce Anti-cancer drugs 21, S3-S11, 2010 | 167 | 2010 |
| Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment R Madrigal‐Burgaleta, MP Berges‐Gimeno, D Angel‐Pereira, ... Allergy 68 (7), 853-861, 2013 | 135 | 2013 |
| Refinement of screening for familial pancreatic cancer DK Bartsch, EP Slater, A Carrato, IS Ibrahim, C Guillen-Ponce, ... Gut 65 (8), 1314-1321, 2016 | 89 | 2016 |
| Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers RL Milne, A Osorio, T Ramón y Cajal, M Baiget, A Lasa, E Diaz-Rubio, ... Breast cancer research and treatment 119, 221-232, 2010 | 87 | 2010 |
| Phase I/II trial to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with pancreatic cancer and an ECOG … T Macarulla, R Pazo-Cid, C Guillén-Ponce, R López, R Vera, M Reboredo, ... Journal of Clinical Oncology 37 (3), 230-238, 2019 | 83 | 2019 |
| Reduced risk of pancreatic cancer associated with asthma and nasal allergies P Gomez-Rubio, JP Zock, M Rava, M Marquez, L Sharp, M Hidalgo, ... Gut 66 (2), 314-322, 2017 | 83 | 2017 |
| Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study AK Win, JG Dowty, JC Reece, G Lee, AS Templeton, JP Plazzer, ... The Lancet Oncology 22 (7), 1014-1022, 2021 | 78 | 2021 |
| Cutaneous metastases of lung cancer MJ Molina Garrido, CG Ponce, JL Soto Martínez, CM y Sevila, AC Mena, ... Clinical and Translational Oncology 8, 330-333, 2006 | 78 | 2006 |
| Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study F Rivera, M Benavides, J Gallego, C Guillen-Ponce, J Lopez-Martin, ... Pancreatology 19 (1), 64-72, 2019 | 73 | 2019 |
| First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II … E Aranda, P García-Alfonso, M Benavides, AS Ruiz, C Guillén-Ponce, ... European journal of cancer 101, 263-272, 2018 | 73 | 2018 |
| Comparison of two frailty screening tools in older women with early breast cancer MJ Molina-Garrido, C Guillen-Ponce Critical reviews in oncology/hematology 79 (1), 51-64, 2011 | 63 | 2011 |
| Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial G Argilés, MP Saunders, F Rivera, A Sobrero, CG Ponce, S Cascinu, ... European journal of cancer 51 (8), 942-949, 2015 | 62 | 2015 |
| PanGen-Fam: Spanish registry of hereditary pancreatic cancer E Mocci, C Guillen-Ponce, J Earl, M Marquez, J Solera, MT Salazar-López, ... European Journal of Cancer 51 (14), 1911-1917, 2015 | 58 | 2015 |
| First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish … J Sastre, B Massuti, G Pulido, C Guillén-Ponce, M Benavides, ... European Journal of Cancer 51 (11), 1371-1380, 2015 | 56 | 2015 |
| Gastric tumours in hereditary cancer syndromes: clinical features, molecular biology and strategies for prevention M Sereno, C Aguayo, CG Ponce, C Gómez-Raposo, F Zambrana, ... Clinical and Translational Oncology 13, 599-610, 2011 | 56 | 2011 |
| Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: the COMBAT/KEYNOTE-202 trial B Bockorny, T Macarulla, V Semenisty, E Borazanci, J Feliu, ... Clinical Cancer Research 27 (18), 5020-5027, 2021 | 53 | 2021 |
